Safety	safety	O	O
profile	profile	O	O
of	of	O	O
a	a	O	O
nicotine	nicotine	S_chemical	O
lozenge	lozenge	O	O
compared	compared	O	O
with	with	O	O
that	that	O	O
of	of	O	O
nicotine	nicotine	S_chemical	O
gum	gum	O	O
in	in	O	O
adult	adult	O	O
smokers	smokers	O	O
with	with	O	O
underlying	underlying	O	O
medical	medical	O	O
conditions	conditions	O	O
:	:	O	O
a	a	O	O
12-week	12-week	O	O
,	,	O	O
randomized	randomized	O	O
,	,	O	O
open-label	open-label	O	O
study	study	O	O
.	.	O	O

BACKGROUND	background	O	O
:	:	O	O
Nicotine	nicotine	S_chemical	O
polacrilex	polacrilex	O	O
lozenges	lozenges	O	O
deliver	deliver	O	O
25	25	O	O
%	%	O	O
to	to	O	O
27	27	O	O
%	%	O	O
more	more	O	O
nicotine	nicotine	S_chemical	O
compared	compared	O	O
with	with	O	O
equivalent	equivalent	O	O
doses	doses	O	O
of	of	O	O
nicotine	nicotine	S_chemical	O
polacrilex	polacrilex	B_chemical	O
gum	gum	I_chemical	O
.	.	O	O

The	the	O	O
increased	increased	O	O
nicotine	nicotine	S_chemical	O
exposure	exposure	O	O
from	from	O	O
the	the	O	O
lozenge	lozenge	O	O
has	has	O	O
raised	raised	O	O
questions	questions	O	O
about	about	O	O
the	the	O	O
relative	relative	O	O
safety	safety	O	O
of	of	O	O
the	the	O	O
lozenge	lozenge	O	O
and	and	O	O
gum	gum	O	O
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
The	the	O	O
objective	objective	O	O
of	of	O	O
this	this	O	O
study	study	O	O
was	was	O	O
to	to	O	O
compare	compare	O	O
the	the	O	O
safety	safety	O	O
profiles	profiles	O	O
of	of	O	O
the	the	O	O
4-mg	4-mg	O	O
nicotine	nicotine	S_chemical	O
lozenge	lozenge	O	O
and	and	O	O
4-mg	4-mg	O	O
nicotine	nicotine	S_chemical	O
gum	gum	O	O
in	in	O	O
smokers	smokers	O	O
with	with	O	O
selected	selected	O	O
label-restricted	label-restricted	O	O
diseases	diseases	O	O
.	.	O	O

METHODS	methods	O	O
:	:	O	O
This	this	O	O
was	was	O	O
a	a	O	O
multicenter	multicenter	O	O
,	,	O	O
randomized	randomized	O	O
,	,	O	O
open-label	open-label	O	O
study	study	O	O
in	in	O	O
adult	adult	O	O
smokers	smokers	O	O
with	with	O	O
heart	heart	O	B_disease
disease	disease	O	I_disease
,	,	O	O
hypertension	hypertension	O	S_disease
not	not	O	O
controlled	controlled	O	O
by	by	O	O
medication	medication	O	O
,	,	O	O
and/or	and/or	O	O
diabetes	diabetes	O	B_disease
mellitus	mellitus	O	I_disease
.	.	O	O

Patients	patients	O	O
were	were	O	O
randomized	randomized	O	O
in	in	O	O
a	a	O	O
1:1	1:1	O	O
ratio	ratio	O	O
to	to	O	O
receive	receive	O	O
the	the	O	O
4-mg	4-mg	O	O
nicotine	nicotine	S_chemical	O
lozenge	lozenge	O	O
or	or	O	O
4-mg	4-mg	O	O
nicotine	nicotine	S_chemical	O
gum	gum	O	O
.	.	O	O

Safety	safety	O	O
assessments	assessments	O	O
were	were	O	O
made	made	O	O
at	at	O	O
baseline	baseline	O	O
and	and	O	O
at	at	O	O
2	2	O	O
,	,	O	O
4	4	O	O
,	,	O	O
6	6	O	O
,	,	O	O
and	and	O	O
12	12	O	O
weeks	weeks	O	O
after	after	O	O
the	the	O	O
start	start	O	O
of	of	O	O
product	product	O	O
use	use	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
Nine	nine	O	O
hundred	hundred	O	O
one	one	O	O
patients	patients	O	O
were	were	O	O
randomized	randomized	O	O
to	to	O	O
treatment	treatment	O	O
,	,	O	O
447	447	O	O
who	who	O	O
received	received	O	O
the	the	O	O
lozenge	lozenge	O	O
and	and	O	O
454	454	O	O
who	who	O	O
received	received	O	O
the	the	O	O
gum	gum	O	O
(	(	O	O
safety	safety	O	O
population	population	O	O
)	)	O	O
.	.	O	O

The	the	O	O
majority	majority	O	O
were	were	O	O
women	women	O	O
(	(	O	O
52.7	52.7	O	O
%	%	O	O
)	)	O	O
.	.	O	O

Patients	patients	O	O
'	'	O	O
mean	mean	O	O
age	age	O	O
was	was	O	O
53.9	53.9	O	O
years	years	O	O
,	,	O	O
their	their	O	O
mean	mean	O	O
weight	weight	O	O
was	was	O	O
193.9	193.9	O	O
pounds	pounds	O	O
,	,	O	O
and	and	O	O
they	they	O	O
smoked	smoked	O	O
a	a	O	O
mean	mean	O	O
of	of	O	O
25.2	25.2	O	O
cigarettes	cigarettes	O	O
per	per	O	O
day	day	O	O
at	at	O	O
baseline	baseline	O	O
.	.	O	O

Five	five	O	O
hundred	hundred	O	O
fifty-three	fifty-three	O	O
patients	patients	O	O
,	,	O	O
264	264	O	O
taking	taking	O	O
the	the	O	O
lozenge	lozenge	O	O
and	and	O	O
289	289	O	O
taking	taking	O	O
the	the	O	O
gum	gum	O	O
,	,	O	O
used	used	O	O
the	the	O	O
study	study	O	O
product	product	O	O
for	for	O	O
>	>	O	O
or	or	O	O
=	=	O	O
4	4	O	O
days	days	O	O
per	per	O	O
week	week	O	O
during	during	O	O
the	the	O	O
first	first	O	O
2	2	O	O
weeks	weeks	O	O
(	(	O	O
evaluable	evaluable	O	O
population	population	O	O
)	)	O	O
.	.	O	O

The	the	O	O
nicotine	nicotine	S_chemical	O
lozenge	lozenge	O	O
and	and	O	O
nicotine	nicotine	S_chemical	O
gum	gum	O	O
were	were	O	O
equally	equally	O	O
well	well	O	O
tolerated	tolerated	O	O
,	,	O	O
despite	despite	O	O
increased	increased	O	O
nicotine	nicotine	S_chemical	O
exposure	exposure	O	O
from	from	O	O
the	the	O	O
lozenge	lozenge	O	O
.	.	O	O

The	the	O	O
incidence	incidence	O	O
of	of	O	O
adverse	adverse	O	B_disease
events	events	O	I_disease
in	in	O	O
the	the	O	O
2	2	O	O
groups	groups	O	O
was	was	O	O
similar	similar	O	O
during	during	O	O
the	the	O	O
first	first	O	O
2	2	O	O
weeks	weeks	O	O
of	of	O	O
product	product	O	O
use	use	O	O
(	(	O	O
evaluation	evaluation	O	O
population	population	O	O
:	:	O	O
55.3	55.3	O	O
%	%	O	O
lozenge	lozenge	O	O
,	,	O	O
54.7	54.7	O	O
%	%	O	O
gum	gum	O	O
)	)	O	O
,	,	O	O
as	as	O	O
well	well	O	O
as	as	O	O
during	during	O	O
the	the	O	O
entire	entire	O	O
study	study	O	O
(	(	O	O
safety	safety	O	O
population	population	O	O
:	:	O	O
63.8	63.8	O	O
%	%	O	O
and	and	O	O
58.6	58.6	O	O
%	%	O	O
,	,	O	O
respectively	respectively	O	O
)	)	O	O
.	.	O	O

Stratification	stratification	O	O
of	of	O	O
patients	patients	O	O
by	by	O	O
sex	sex	O	O
,	,	O	O
age	age	O	O
,	,	O	O
extent	extent	O	O
of	of	O	O
concurrent	concurrent	O	O
smoking	smoking	S_chemical	O
,	,	O	O
extent	extent	O	O
of	of	O	O
product	product	O	O
use	use	O	O
,	,	O	O
and	and	O	O
severity	severity	O	O
of	of	O	O
adverse	adverse	O	B_disease
events	events	O	I_disease
revealed	revealed	O	O
no	no	O	O
clinically	clinically	O	B_disease
significant	significant	O	I_disease
differences	differences	O	O
between	between	O	O
the	the	O	O
lozenge	lozenge	O	O
and	and	O	O
gum	gum	O	O
.	.	O	O

The	the	O	O
most	most	O	O
common	common	O	O
adverse	adverse	O	B_disease
events	events	O	I_disease
were	were	O	O
nausea	nausea	O	S_disease
(	(	O	O
17.2	17.2	O	O
%	%	O	O
and	and	O	O
16.1	16.1	O	O
%	%	O	O
;	;	O	O
95	95	O	O
%	%	O	O
CI	ci	O	O
,	,	O	O
-3.7	-3.7	O	O
to	to	O	O
6.0	6.0	O	O
)	)	O	O
,	,	O	O
hiccups	hiccups	O	S_disease
(	(	O	O
10.7	10.7	O	O
%	%	O	O
and	and	O	O
6.6	6.6	O	O
%	%	O	O
;	;	O	O
95	95	O	O
%	%	O	O
CI	ci	O	O
,	,	O	O
0.5	0.5	O	O
to	to	O	O
7.8	7.8	O	O
)	)	O	O
,	,	O	O
and	and	O	O
headache	headache	O	S_disease
(	(	O	O
8.7	8.7	O	O
%	%	O	O
and	and	O	O
9.9	9.9	O	O
%	%	O	O
;	;	O	O
95	95	O	O
%	%	O	O
Cl	cl	O	O
,	,	O	O
-5.0	-5.0	O	O
to	to	O	O
2.6	2.6	O	O
)	)	O	O
.	.	O	O

Serious	serious	O	B_disease
adverse	adverse	O	B_disease
events	events	O	I_disease
were	were	O	O
reported	reported	O	O
in	in	O	O
11	11	O	O
and	and	O	O
13	13	O	O
patients	patients	O	O
in	in	O	O
the	the	O	O
respective	respective	O	O
groups	groups	O	O
.	.	O	O

Fewer	fewer	O	O
than	than	O	O
6	6	O	O
%	%	O	O
of	of	O	O
patients	patients	O	O
in	in	O	O
either	either	O	O
group	group	O	O
were	were	O	O
considered	considered	O	O
by	by	O	O
the	the	O	O
investigator	investigator	O	O
to	to	O	O
have	have	O	O
a	a	O	O
worsening	worsening	O	O
of	of	O	O
their	their	O	O
overall	overall	O	O
disease	disease	O	O
condition	condition	O	O
during	during	O	O
the	the	O	O
study	study	O	O
.	.	O	O

The	the	O	O
majority	majority	O	O
of	of	O	O
patients	patients	O	O
(	(	O	O
>	>	O	O
60	60	O	O
%	%	O	O
)	)	O	O
experienced	experienced	O	O
no	no	O	O
change	change	O	O
in	in	O	O
their	their	O	O
disease	disease	O	O
status	status	O	O
from	from	O	O
baseline	baseline	O	O
.	.	O	O

CONCLUSION	conclusion	O	O
:	:	O	O
The	the	O	O
4-mg	4-mg	O	O
nicotine	nicotine	S_chemical	O
lozenge	lozenge	O	O
and	and	O	O
4-mg	4-mg	O	O
nicotine	nicotine	S_chemical	O
gum	gum	O	O
had	had	O	O
comparable	comparable	O	O
safety	safety	O	O
profiles	profiles	O	O
in	in	O	O
these	these	O	O
patients	patients	O	O
with	with	O	O
label-restricted	label-restricted	O	O
medical	medical	O	O
conditions	conditions	O	O
.	.	O	O

